| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Lomitapide-d8 targets microsomal triglyceride transfer protein (MTP), an enzyme essential for the assembly and secretion of apolipoprotein B-containing lipoproteins. Lomitapide inhibits MTP with an IC50 of 8 nM. By inhibiting MTP, Lomitapide reduces the production of very low-density lipoproteins (VLDL) and lowers plasma lipid levels.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, Lomitapide-d8 is used as an internal standard for the quantification of Lomitapide. The compound does not exhibit intrinsic pharmacological activity beyond that of Lomitapide but serves as a quantitative tool for studying MTP inhibition and drug metabolism in cell-based systems. Lomitapide inhibits MTP with an IC50 of 8 nM. |
| ln Vivo |
In vivo, Lomitapide-d8 is used in pharmacokinetic and pharmacodynamic studies to trace the distribution and metabolism of Lomitapide in animal models. The deuterium label allows for precise quantification of the drug and its metabolites in plasma and tissues using mass spectrometry. Lomitapide is used in the treatment of homozygous familial hypercholesterolemia.
|
| Enzyme Assay |
As an internal standard, Lomitapide-d8 is used in analytical assays such as LC-MS/MS. Typical protocols involve spiking the labeled compound into biological samples prior to extraction and analysis. The labeled compound co-elutes with the unlabeled Lomitapide but is detected at a different mass-to-charge ratio, allowing for precise quantification and correction for matrix effects.
|
| Cell Assay |
In vitro cell-based experiments using Lomitapide-d8 involve treating cells with the compound and analyzing its uptake and metabolism by mass spectrometry. The compound can be used to study MTP inhibition and the pharmacokinetics of Lomitapide in various cell types.
|
| Animal Protocol |
In vivo animal studies using Lomitapide-d8 involve administering the compound to rodents via oral gavage. Blood samples are collected at various time points, and the concentration of the labeled compound is measured by mass spectrometry. Tissue distribution and metabolic profiling can also be performed.
|
| ADME/Pharmacokinetics |
Lomitapide-d8 exhibits pharmacokinetic properties similar to those of unlabeled Lomitapide. Lomitapide is orally bioavailable and has good tissue penetration. It is metabolized in the liver and excreted primarily in feces. The deuterium label provides a distinct mass shift for analytical detection without significantly altering the compound's physicochemical properties.
|
| Toxicity/Toxicokinetics |
Lomitapide-d8 is considered safe for research use at typical concentrations. Unlabeled Lomitapide has a well-established safety profile as an approved therapeutic but can cause adverse effects such as gastrointestinal disturbances and liver enzyme elevations. As a stable isotope-labeled compound, it is not intended for therapeutic use.
|
| References |
|
| Additional Infomation |
Lomitapide-d8 has a molecular formula of C39H29D8F6N3O2 and a molecular weight of 701.77. It is the deuterium-labeled form of Lomitapide (AEGR-733; BMS-201038), a potent MTP inhibitor with an IC50 of 8 nM. It is intended for use as an internal standard for the quantification of lomitapide by GC- or LC-MS.
|
| Molecular Formula |
C39H37F6N3O2
|
|---|---|
| Molecular Weight |
693.720411062241
|
| Exact Mass |
701.329
|
| CAS # |
2459377-96-7
|
| Related CAS # |
Lomitapide;182431-12-5
|
| PubChem CID |
163322374
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
8.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
50
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([H])([H])(C1(C2=CC=CC=C2C2=CC=CC=C12)C(=O)NCC(F)(F)F)C([H])([H])C([H])([H])C([H])([H])N1CCC(NC(C2C=CC=CC=2C2C=CC(C(F)(F)F)=CC=2)=O)CC1
|
| InChi Key |
MBBCVAKAJPKAKM-WKAGHQRMSA-N
|
| InChi Code |
InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)/i7D2,8D2,21D2,22D2
|
| Chemical Name |
9-[1,1,2,2,3,3,4,4-octadeuterio-4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)fluorene-9-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4415 mL | 7.2075 mL | 14.4150 mL | |
| 5 mM | 0.2883 mL | 1.4415 mL | 2.8830 mL | |
| 10 mM | 0.1442 mL | 0.7208 mL | 1.4415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
